New Director, Business Development Named
Genome Atlantic is pleased to announce Andy Stone as our new Director of Business Development. Andy joined Genome Atlantic in January, 2013 as Business Development Officer, bringing a BSc and MBA (Management of Innovation) from McMaster University, and over 15 years’ experience in technology development and commercialization.
His success in quickly furthering our business development efforts through effective strategy and thorough execution was a key indicator of his ability to lead this aspect of our organization.
Before joining our team, Andy employed his passion for the power of technology by matching industry needs with the research capacity of the National Research Council here in Halifax. There, he worked alongside leading researchers in fields from health care to biofuels, using technologies like genotyping and metabolomics, and helped facilitate the transfer of knowledge and expertise to clients in a wide range of industries.
Previously, Andy worked at Hospira (a spin-out from Abbott), implementing technology solutions in hospital settings, which was particularly useful in his recent role as project manager for a pilot project at Capital Health that uses genomic information to provide more accurate diagnosis for lung cancer to better inform patient management.
We look forward to Andy’s continued contribution to our team in this advanced role.